Kornimate/medical-research-clean huggingface dataset:
adjunctive effect of pulsed electromagnetic field on quadriceps muscle strength after burn injury

Conditions: Lower Limb Burn

Summary: the aim of this study is to examine whether pulsed electromagnetic field therapy combined with strengthening exercises will have a positive effect on quadriceps muscle strength in lower limb burn .

• subjects: sixty patients with lower limb burn, subdivided into two groups each one has 30 patients. * group (a) = pulsed electromagnetic field therapy and quadriceps strengthening exercises group. * group (b) = quadriceps strengthening exercises group. • equipment and tools: 1. measurements tools: isokinetic dynamometer : to measure the quadriceps muscle peak torque before the treatment and after 8 weeks of treatment for both groups. 2. therapeutic tools: pulsed electromagnetic field therapy device and free weights for strengthening of quadriceps muscle.

Eligibility criteria:
inclusion criteria: * - patients are males. * their age will range from (25-40) years. * patients will suffer from second-degree burn ( partial thickness of thermal injury). * total body surface area (tbsa) for the burns will be ranged from 20% to 35% . * they will be selected from outpatient clinic of faculty of physical therapy and burn unit at om el-obour hospital. * patients will begin the training program after complete wound healing. * all patients will receive traditional physical therapy program in the form of range of motion exercise, stretching, splinting, massage, functional training for ambulation and activities of daily living. * patients will be given their informed consent. exclusion criteria: * - patients who participate in any rehabilitation program to improve muscle strength prior to the study. * musculoskeletal disorders that will impair performance during training and tests. * equilibrium disorders. * uncontrolled cardiovascular or pulmonary diseases . * neurological and renal disorders. * metabolic or vascular disease with a neurological component such as diabetes, * malignant conditions. * psychiatric illness, severe behavior or cognitive disorders. * subjects with burn to the posterior thigh with knee flexion contracture, which affected the function of the quadriceps muscle. * lower limb lymphedema or lipoedema. * athletic subjects. * subjects with morbid obesity.
a single arm, tolerability and safety phase iv study of fulvestrant(faslodex® ) as 2nd line and later therapy in postmenopausal women with locally advanced or metastatic breast cancer

Conditions: Locally Advanced or; Metastatic Breast Cancer

Summary: this single-arm study aims to assess the safety and tolerability profile of fulvestrant(faslodex®) as 2nd line and later therapy in postmenopausal women with locally advanced or metastatic breast cancer. the primary objective is to evaluate the adverse events after fulvestrant (faslodex®) for about 6 months

this study is a phase 4, single-arm, safety and tolerability study of fulvestrant (faslodex®) as 2nd line therapy in postmenopausal women with locally advanced or metastatic breast cancer. all of enrolled patients in this study will be injected fulvestrant (faslodex®). this study will be performed for about 3 years and approximately 100 patients(actual target will be 80 treated patients) will be enrolled in about 10 investigational sites. after obtaining the written informed consent from the patients, the information of demographic and medical history will be collected and laboratory tests will be performed. patients who meet the inclusion/exclusion criteria will be injected the fulvestrant (faslodex®) 500mg/month for about 6 months with an additional 500mg dose given 14 days after the initial dose injection. the information of adverse events will be collected after the 1st dose of ip injection. in case that the evaluation of tumor response might be performed in regular clinical practice, those data will also be collected as well. the quality of life will also be measured.

Eligibility criteria:
inclusion criteria: * post menopausal status women * outpatient or inpatient with locally advanced or metastatic breast cancer who have failed with prior anti-estrogen therapy. * estrogen receptor positive * radiographic progression of disease after the prior therapy * patients who agree to participate in this study and sign the informed consent exclusion criteria: * patients who are treated with fulvestrant * patients who are being treated with the other antitumor agents * pregnancy or lactating women * history of hypersensitivity to any of included ingredients (eg. castor oil) * patients who are considered not fit for the study by investigators * patients who have severe dysfunction of liver or kidney
covid-19 stroke apical lung examination study

Conditions: Covid19; Stroke, Acute; Stroke, Ischemic; Stroke Hemorrhagic

Summary: multi-centre prospective study evaluating computed tomography angiography studies performed for stroke patients as a diagnostic and prognostic imaging biomarker.

diagnosis of coronavirus disease 2019 (covid-19) relies on clinical features and reverse-transcriptase polymerase chain reaction (rt-pcr) testing. the latter is constrained by limited sensitivity and a timescale of hours to yield results, with no point-of-care test widely available. a dedicated computed tomography study of the chest is likely to be more sensitive than rt-pcr for covid-19. carotid computed tomography angiography (cta) is a routine acute stroke investigation and includes the lung apices. we aim to assess the lung apices on cta for ground glass opacification and compare this with covid-19 rt-pcr test results and clinical outcome measures.

Eligibility criteria:
inclusion criteria: all adult patients presenting with clinical features of acute ischaemic stroke undergoing investigation with computed tomography angiography at presentation. exclusion criteria: poor image quality. no radiologist report available. computed tomography angiography performed in a non-acute setting.

Keywords: covid stroke ct cta
open-label study of the safety and activity of oprozomib in patients with hematologic malignancies

Conditions: Multiple Myeloma; Waldenstrom Macroglobulinemia

Summary: the purpose of this study is to determine the maximum tolerated dose (mtd), activity, and safety of oprozomib in patients with hematologic malignancies.


Eligibility criteria:
inclusion criteria: phase 1b * histologically confirmed diagnosis of a hematologic malignancy, excluding patients with acute leukemia or mds. * relapsed after standard therapy for their malignancy and considered to be an appropriate candidate for a phase 1 clinical study by their treating physician. phase 2 * multiple myeloma with measurable disease * waldenström macroglobulinemia with symptomatic relapse * eastern cooperative oncology group (ecog) performance status 0-2. ethical/other * patients must sign a written informed consent form in accordance with federal, local, and institutional guidelines. * female patients of childbearing potential must have a negative serum or urine pregnancy test and agree to use effective contraception. male patients must use an effective barrier method of contraception. exclusion criteria: * chemotherapy with approved or investigational anticancer therapeutics, including steroid therapy intended to treat underlying malignancy, within 3 weeks prior to first dose or 6 weeks for antibody therapy. * radiation therapy within 3 weeks prior to first dose. radioimmunotherapy within 8 weeks prior to first dose. localized radiation therapy within 1 week prior to first dose. * immunotherapy within 3 weeks prior to first dose (except for antibody therapy, where 6 weeks is required). * prior stem cell transplant (sct) therapy (autologous sct within the prior 8 weeks; allogeneic sct within the prior 16 weeks). patients with prior allogeneic sct should not have evidence of moderate-to-severe graft-vs-host disease (gvhd; as defined in filipovich 2005). * evidence of central nervous system (cns) lymphoma. * prior treatment with carfilzomib unless in the phase 2. * major surgery within 3 weeks prior to first dose. * symptomatic congestive heart failure, ischemia, conduction abnormalities, or myocardial infarction within 6 months. * acute active infection requiring systemic antibiotics, antivirals, or antifungals. * known or suspected human immunodeficiency virus (hiv) infection or patients who are hiv seropositive. * active hepatitis a, b, or c infection. * significant neuropathy (grade 3, grade 4, or grade 2 with pain) at the time of the first dose. * patients with pleural effusions requiring routine thoracentesis or ascites requiring routine paracentesis. * history of previous clinically significant gi bleed in the last 6 months prior to first dose. * female patients who are pregnant or lactating.

Keywords: multiple myeloma waldenstrom macroglobulinemia
examination of psychological tools and tracking in an online intervention for type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: the goal of the research is to optimize an online and mobile multicomponent 12-month diet and lifestyle intervention for improving the blood glucose control of individuals with type 2 diabetes.

the core of the program, administered to all participants, includes recommendations to follow a very low carbohydrate, ketogenic diet. the researchers will test whether adding the following experimental components will enhance the intervention's ability to improve health outcomes: (1) active vs. periodic self-monitoring of dietary intake using an "app"; (2) training vs. no training in positive affect; and (3) training vs. no training in mindfulness and mindful eating.

Eligibility criteria:
inclusion criteria: * weight: body mass index of 25-45 kg/m2 or greater. * current hba1c of 6.5% or higher * regular access to the internet exclusion criteria: * taking glucose lowering medications other than metformin * being pregnant or breastfeeding * currently undergoing cancer treatments * active use of a weight loss program or medications * self-reported impaired renal or hepatic function * self-reported untreated thyroid condition * vegetarian or vegan * weight loss surgery within the past year * medical concerns that prevent participants from following the assigned protocol
preventing age-related weight gain in the workplace with daily weighing

Conditions: Weight Gain

Summary: to examine the effectiveness of daily weighing to prevent age-related weight gain.

cornell employee's were recruited for a two-year weight gain prevention study. height and weights were taken in our metabolic center. they were randomized into two group. the experimental group was given an internet based scale and asked to weigh themselves every morning immediately after rising. the other group was asked to return at the end of the study when they height and weight will again be measured.

Eligibility criteria:
inclusion criteria: * healthy, non-diabetic exclusion criteria: * history of eating disorders
evaluation of new mri sequences including 3d-fgapsir for the optimization of inflammatory spinal cord lesions research

Conditions: Spinal Cord Injuries

Summary: * verification of inclusion and non-inclusion criteria * information and collection of consent * standard imaging protocol prescribed as part of the usual treatment: sagittal t1 and t2 slices after injection of contrast product (gadolinium), 3d stir and 3d psir sequence. * 3d fgapsir sequence at the level of the cervical cord for the duration of the additional sequence is 10 minutes, for a total examination time of 40 minutes (instead of 30 minutes)

* verification of inclusion and non-inclusion criteria * information and collection of consent * standard imaging protocol prescribed as part of the usual treatment: sagittal t1 and t2 slices after injection of contrast product (gadolinium), 3d stir and 3d psir sequence. * 3d fgapsir sequence at the level of the cervical cord for the duration of the additional sequence is 10 minutes, for a total examination time of 40 minutes (instead of 30 minutes)

Eligibility criteria:
inclusion criteria: * patient over 18 years old * to benefit from a medullary exploration planned by 3t mri as part of a first evaluation or a reassessment of inflammatory involvement of the nevrax * express consent to participate in the study * affiliate or beneficiary of a social security scheme exclusion criteria: * patient benefiting from a legal protection measure * pregnant, parturient or breastfeeding woman * absolute or relative contraindication to mri
research network for neonatal diseases induced by tissular fetomaternal alloimmunization

Conditions: Glomerulonephritis, Membranous; Neonatal Diseases and Abnormalities; Hemochromatosis

Summary: problems of compatibility between a mother and her child are frequent. the most well-known case can be illustrated by the fetomaternal blood group incompatibility (rhesus factor) which can induce severe anemia of the fetus. the investigators recently proved that incompatibility between mother and child can concern an organ leading to a tissular alloimmunization. for example, neonatal membranous glomerulonephritis (a kidney disease) can result from this mechanism. the purpose of this network is to detect and study neonatal diseases induced by tissular fetomaternal alloimmunization. the detection of these diseases will be performed by the mother's serum analysis.


Eligibility criteria:
inclusion criteria: mothers having a child suffering from: * neonatal membranous glomerulonephritis * unexplained neonatal tubular defect * unexplained thrombotic microangiopathy * neonatal hemochromatosis exclusion criteria: * any cause explaining the child's disease

Keywords: fetomaternal tissular alloimmunization mothers having a child suffering from: neonatal membranous glomerulonephritis unexplained neonatal tubular defect unexplained thrombotic microangiopathy neonatal hemochromatosis
developmental trajectory of gene and life participation in children with developmental delay

Conditions: Genetics; Life Participation

Summary: the goal of this observational study is to learn the factors affecting the quality of life in children's development. the main hypothesis for this study is: if the level of well-being increases in age, could the quality of life be enhanced in terms of function and participation? participant will be given assessment every year for five years in total. no intervention will be given during the whole study period.


Eligibility criteria:
normal developing children inclusion criteria: * agreeing in consent * in the age range of 6-15 years old exclusion criteria: * diseases of central nervous system * diseases of neuromuscular * nature deficit disorder * genetic disorder * sensory integration disorder * auditory disorder development delay children inclusion criteria: * agreeing in consent * in the age range of 6-15 years old * diagnosed of developmental delay exclusion criteria: * diseases of central nervous system * diseases of neuromuscular * nature deficit disorder * genetic disorder * sensory integration disorder * auditory disorder

Keywords: developmental delay life participation quality of life whole-exome sequencing gene children development
study of neurobehavioral outcome in children or adolescents with closed head injuries

Conditions: Head Injuries, Closed

Summary: objectives: i. determine the relationship of closed head injury (chi) severity, focal brain lesions, and the age at injury to the development of working memory, inhibition, and metacognitive skills in children or adolescents with chi of varying severity. ii. assess the development of working memory, inhibition, and metacognitive skills in relation to discourse functions, scholastic achievement, and adaptive behavior in these patients. iii. determine the relationship between impaired inhibition, metacognitive skills, and the emergence of psychiatric disorder in these patients.

protocol outline: this is a multicenter study. patients are assigned to one of two study groups based on when the closed head injury (chi) occurred. study i (chi that occurred at least 3 years ago): patients undergo standardized and computer based testing of cognition, attention, planning ability, organizational ability, memory, fine motor functioning, reading and math skills, language, and behavioral and emotional functioning on day 1. patients then undergo brain magnetic resonance imaging (mri) on the same day. while each patient undergoes testing, the patient's parent/guardian answers interview questions regarding the patient's functional and emotional status since the injury, and the family's functional status, exposure to stressful events, and psychiatric history. prior to the visit, a questionnaire regarding classroom behaviors, such as ability to focus in school and perform class work, is mailed to each patient's teacher. study ii (recently diagnosed chi): patients undergo neurobehavioral and psychological testing as in study i once during hospitalization or soon after discharge, and then at 3, 6, 12, and 24 months. patients undergo brain mri at 3 months. while each patient undergoes testing, the patient's parent/guardian answers interview questions as in study i. prior to each visit, the same questionnaire as in study i is mailed to each patient's teacher. both studies: a brief written summary of the patient's test results may be provided to the patient, parent/guardian, school, pediatrician, or other professional at the request of the patient and parent/guardian.

Eligibility criteria:
* study i: closed head injury (chi) that occurred at least 3 years ago * study ii: recently diagnosed chi * both studies: eligible if chi resulted from acceleration, deceleration, or impact by a blunt object (e.g., motor vehicle accidents, pedestrian-vehicular injury, falls, assault except child abuse by caregiver) preinjury emotional/behavioral problems allowed except mental retardation, autism, schizophrenia, or pervasive developmental disorder that would confound evaluation of cognitive function

Keywords: neurologic and psychiatric disorders rare disease
adoptive cell therapy plus chemotherapy and radiation after surgery in treating patients with colorectal cancer

Conditions: Colorectal Cancer; Neoplasms; Intestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases

Summary: the purpose of this study is to evaluate the efficacy of autologous tumor lysate-pulsed dendritic and cytokine-induced killer cells (dc-cik) for colorectal cancer (crc).

60 patients with stageⅰ\~ ⅲ crc, who had received surgery and kept their tumor tissue, will be randomly divided into group a (receive dc-cik treatment, chemotherapy and radiotherapy) or group b (just receive chemotherapy and radiotherapy), and the randomize ratio will be 1:1. patients in group a will receive 3 cycles of autologous tumor lysate pulsed dc-cik cells treatment (every 4 weeks) and 4 cycles chemo-radiotherapy. patients in group b will receive only 4 cycles chemo-radiotherapy.

Eligibility criteria:
inclusion criteria: * 18\~80 years old; * histologically confirmed with colorectal cancer at stage ⅰ\~ⅲ; * patients who can accept curative operations; * patients who have a life expectancy of at least 3 months; * eastern cooperative oncology group (ecog) performance status was 0 - 1. exclusion criteria: * hemoglobin\<8.0 g/dl,platelet count \<75 x 10\^9/l; alt, ast, bun and cr more than normal limits on 3.0 times ; * known or suspected allergy to the investigational agent or any agent given in association with this trial; * pregnant or lactating patients; * known history of human immunodeficiency virus (hiv), hepatitis c virus (hcv) or treponemapallidun (tp) infection; * patients who are suffering from serious autoimmune disease; * history of organ allograft; * patients who had distant metastases; * patients who had active infection; * prior use of any anti-cancer treatment in 30 days; * now or recently will join another experimental clinical study ; * other situations that the researchers considered unsuitable for this study.

Keywords: colorectal cancer dc-cik autologous tumor lysate
a trial to assess the efficacy and safety of octreotide subcutaneous depot in patients with pld

Conditions: Polycystic Liver Disease

Summary: the purpose of the trial is to compare the effectiveness and safety of 2 treatment regimens of cam2029 (given weekly or every 2 weeks) to placebo in participants with symptomatic pld, either isolated as in autosomal dominant pld (adpld) or associated with autosomal dominant polycystic kidney disease (adpkd). in the treatment period of the trial, participants will be allocated at random to 1 of the 3 treatment arms in a 1:1:1 ratio. after completing the treatment period (53 weeks) participants may proceed to a 120-week open-label extension part of the trial and then only receive the same cam2029 treatment. the active ingredient in cam2029, octreotide, is administered as a subcutaneous depot using camurus' fluidcrystal® technology.


Eligibility criteria:
inclusion criteria: * male or female patient, ≥18 years at screening * diagnosis of pld (associated with adpkd or isolated as in adpld) as defined by httlv ≥1800 ml/m at screening * presence of at least 1 of the following pld-related symptoms within 2 weeks before screening: bloating, fullness in abdomen, lack of appetite, feeling full quickly after beginning to eat, acid reflux, nausea, rib cage pain or pressure, pain in side, abdominal pain, back pain, shortness of breath after physical exertion, limited in mobility, concern about abdomen getting larger, dissatisfied by the size of abdomen * not a candidate for, or not willing to undergo, surgical intervention for hepatic cysts during the trial exclusion criteria: * surgical intervention for pld within 3 months before screening * treatment with a somatostatin analogue (ssa) within 3 months before screening * non-responsive to previous treatment of pld with an ssa as per the investigator's assessment * systematic cholelithiasis within 3 months before screening or previous medical history of cholelithiasis induced by ssas unless treated with cholecystectomy * presence of extrahepatic cysts that, in the investigator's opinion, may prevent the patient from safely participating in the trial * severe kidney disease, as defined by egfr \<30 ml/min/1.73\^m2 * severe liver disease defined as liver cirrhosis of child-pugh class c * any other current or prior medical condition that may interfere with the conduct of the trial or the evaluation of its results in the opinion of the investigator

Keywords: polycystic liver pld adpld adpkd pcld height-adjusted total liver volume httlv cam2029 positano